Back to search results

Proton Therapy for Gynecologic Cancers After Surgery

This study is testing a type of radiation called Whole Pelvis (WP) Pencil Beam Scanning Proton Radiation (PBS PRT) for women who have had surgery for cervical or uterine (endometrial) cancer. This treatment is given after surgery to help prevent the cancer from coming back. Researchers want to see how much stomach and bowel (gastrointestinal or GI) side effects people experience with this proton therapy. You may be able to join if you are 18 or older, have confirmed cervical or endometrial cancer, and need radiation after surgery. The study plans to enroll 25 participants and is currently unclear on its recruitment status.

Study design
This is a Phase II, single-arm study, meaning all 25 participants will receive the same treatment. It is being conducted at one institution across multiple locations.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your GI side effects will be checked for up to 6 months after your treatment ends during follow-up visits.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05758688

PROton Therapy for Post Surgical Treatment of GYNecologic Cancer

Recruiting
PHASE2Ages 18+InterventionalTreatment
Abramson Cancer Center at Penn Medicine
~25 participants
Updated 2026-06-10 on ClinicalTrials.gov
What's tested:Whole Pelvis (WP) Pencil Beam Scanning Proton Radiation (PBS PRT)

At a glance

Recruiting sites
3 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Acute clinician-reported gastrointestinal (GI) toxicity.
Measured over Up to 6 months after end of treatment at follow up visits

Conditions

Cervical Cancer
Uterine Cancer
Endometrial Cancer

Explore related trials

Cervical CarcinomaEndometrial Carcinoma

Where it's being run

3 sites across 2 states
Pennsylvania2
New Jersey1

Study leadership

  • Neil K Taunk, MD, MSCTS · PRINCIPAL_INVESTIGATOR · University of Pennsylvania

Who to contact

Project Manager
[email protected]
215-662-3790
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Histologically confirmed cervical or endometrial cancer
Indication for adjuvant whole pelvic radiation therapy, with or without systemic therapy
Age of 18 years or older
Written informed consent
ECOG of 0-2 within 3 months of enrolling

Exclusion

Prior course of pelvic radiation
Metastatic disease outside of the pelvis
Active inflammatory bowel disease
Incapacity to provide informed consent

What this trial measures

  • Acute clinician-reported gastrointestinal (GI) toxicity.Up to 6 months after end of treatment at follow up visits

    Determine the rate of acute clinician-reported gastrointestinal (GI), with the Common Terminology Criteria for Adverse Events (CTCAE v5.0) criteria. Acute GI grade 2 or higher toxicity is the primary powering endpoint.